New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
World Federation of hemphilia (WFH) shared on X about a recent article by Davide Matino et al, published in Haemophilia Journal:
”A new Canadian study explores outcomes for people with hemophilia A (12+) who switched to a longer-acting treatment, looking at bleeding, quality of life, infusion frequency, and treatment satisfaction.”
Title: Canadian Clinical Experience on Switching From Standard Half-life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half-life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada
Authors: Davide Matino, Anthony K. C. Chan, Kay Decker, Emma Iserman, Andrea N. Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Read the Full Article on Haemophilia Journal

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 15:21Wolfgang Miesbach։ Gene Therapy for Haemophilia B Is Cheaper Than Lifelong Factor IX Prophylaxis in Sweden
-
Nov 13, 2026, 15:10Sally Mandour: Ringed Sideroblasts in Peripheral Blood
-
Nov 13, 2026, 14:58Lorena Arranz: The Power of Patient Engagement in Advancing MPN Research
-
Nov 13, 2026, 14:46Shehab Mohamed: SGLT2 Inhibitors in Anemia Management
-
Nov 13, 2026, 14:25Dino Mehic: Targeting TFPI in Unexplained Bleeding Disorders
-
Nov 13, 2026, 14:19Bahar Artım Esen: Rituximab in Antiphospholipid Syndrome
-
Nov 13, 2026, 14:13Tagreed Alkaltham: What If One Blood Donation Could Produce Units Of Blood?
-
Nov 13, 2026, 13:27Shirley D’Sa: Connecting European and Mayo Clinic Experts in MGCS Research and Care
-
Nov 13, 2026, 13:20Josie Sirna: Representing the Thalassemia Community at Canada’s Rare Disease Conference in Halifax